Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOPAD PEN: AVT02 PFS vs Autoinjector in Healthy Volunteers
NCT03983876Phase 1Completed
- Sponsor
- Alvotech
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AVT02 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and 1 more (2 arms), sponsored by Alvotech. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration, Area under the plasma concentration-time curve from time zero extrapolated to infinity and 1 more. Started Jul 2019; status: completed.
02
Drugs
AVT02
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)plaque psoriasis
Beyond the preview
Go deeper on NCT03983876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983876.